The Department of Justice (DOJ) and the Federal Trade Commission (FTC) are collaborating to host a series of listening sessions aimed at exploring ways to reduce drug prices in the United States through enhanced competition. These sessions are particularly focused on identifying and addressing anticompetitive conduct by pharmaceutical companies that hinders the entry of generic and biosimilar drugs into the market.

During these sessions, stakeholders, including healthcare professionals, consumer advocates, and industry representatives, will have the opportunity to share their insights and experiences regarding the current state of drug pricing and competition. The DOJ and FTC are particularly interested in understanding how existing practices may be limiting access to affordable medications and what regulatory changes could facilitate a more competitive environment.

The initiative comes in response to growing concerns about high prescription drug prices in the U.S., which have been a significant burden for many Americans. By fostering competition, the DOJ and FTC aim to create a marketplace where consumers can benefit from lower prices and increased availability of essential medications.